In the near future it is likely that newer agents like dual GLP‐1/GIP or even triple GLP‐1/GIP/Glucagon agonists will play a prominent role in treatment of patients with T2DM and MASLD/MASH. This evidence concerns the gene GIP and type 2 diabetes mellitus.